Notícias e Atividades da ANI Pharmaceuticals

ANI Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

ANI Pharmaceuticals é uma empresa listada sob o símbolo ANIP (US).

Eles estão dentro:

• Biotecnologia50%
• Farmacêutica50%

Fusão, aquisição e financiamento envolvendo ANI Pharmaceuticals.

• ANI Pharmaceuticals adquiriu Alimera Sciences (publicado em 16 de setembro de 2024).
• ANI Pharmaceuticals has announced the acquisition of Alimera Sciences  (publicado em 26 de junho de 2024).

Veja o organograma con seus 31 executivos principais

Biografias mais buscadas da ANI Pharmaceuticals

• Nikhil Lalwani, Director, President and Chief Executive Officer
• Antonio Pera, Director
• Thomas Haughey, Director

Criar um alerta
para seguir os movimentos de executivos da ANI Pharmaceuticals.

ANI Pharmaceuticals possui 2.349 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).

Popular M&A news in Biotecnologia

• Taiho Pharmaceutical has announced the acquisition of Araris Biotech  (publicado em 3 de abril de 2025).
• Maxion Therapeutics acaba de anunciar uma arrecadação de fundos de 72 milhões de dólares. (publicado em 3 de abril de 2025).
• Lantheus Holdings adquiriu Evergreen Theragnostics (publicado em 2 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de ANI Pharmaceuticals

• ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
• ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients
• ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
• ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
• ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
• ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
• ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
• ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
• ANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of Directors
• ANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable Growth
• View more press releases Close

Redes sociais sobre ANI Pharmaceuticals

• ANI Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• ANI Pharmaceuticals na LinkedIn, Twitter e YouTube